Chris Stevens Email & Phone Number

Greater Boston Area, Ma, Us

Sheffield, Yorkshire, Gb

Independent consultant for the biopharmaceutical industry in the areas of gastroenterology, hepatology, immunology, rare disease and inflammation

Boston, Ma, Us

Arsanis developed a monoclonal antibody combination product targeting Staphylococcus aureus toxins from IND filing through to Phase 2 for the prevention of Staphylococcus aureus pneumonia in mechanically ventilated patients.

Us

Gastroenterology expert as needed for clinical trial activities

Burlington, Ma, Us

Senior Advisor for drug development and medical affairs activities reporting to the CMO

Gastrointestinal expert on team with BLA filing for vedolizumab with FDA and EMA including fast track application with FDA, and participation with Sponsor at the Scientific Advisory Panel Meeting at FDA. Vedolizumab was ultimately approved for the treatment of both Crohn's disease and ulcerative colitis indications in both the United States and Europe.

Assisted Biomodels establishing relevant inflammatory bowel disease rodent models incorporating animal endoscopy as an outcome demonstrating endoscopic scores of colitis correlated with the extent of histopathological disease in these models.

Physician on team assisting with clinical sections of IND filing that was accepted by the FDA and designing Phase 1 clinical trials for a small molecule indicated for the treatment of obesity

Lexington, Ma, Us

Functioned as medical director on surotomycin program discovered at Cubist for the treatment of C. difficile infection from IND through end of Phase 2

Indianapolis, Indiana, Us

Eli Lilly acquired Alnara in 2010 and I was retained by Lilly as a consultant through a transition period

Responsible for building clinical team completing 2 safety trials and leading clinical activities that led to the successful NDA filing for Alnara's lead candidate liprotamase indicated for the treatment of exocrine pancreatic insufficiency. Presented at the FDA Gastrointestinal advisory panel for liprotamase

Paris, France, Fr

I was the gastroenterology expert on a team investigating in-licensing opportunities for products with gastrointestinal indications

Boston, Ma, Us

Physician scientist with a clinical focus on the care of patients with inflammatory bowel disease and research interest in the pathobiology of the intestinal mucosal inflammation of Crohns disease and ulcerative colitis

Brussels, Be

Gastroenterology expert on the team responding to questions from EMA for the filing of certolizumab for the treatment of Crohn's disease

Assisted development team with clinical trial designs for Phase 2 ulcerative colitis studies

Wrote clinical sections of IND, designed and implemented three Phase I clinical trials and designed the phase 2 trial for liprotamase indicated for the treatment of exocrine pancreatic insufficiency

Involved in all medical aspects of the company including clinical development, clinical operations, fund raising, alliance management, and ultimately sale of the company

Boston, Ma, Us

NIH funded physician scientist investigating the role of mucosal inflammatory mediators in inflammatory bowel diseases

Md, Medicine

Ba, Chemistry